Molecular pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 5835-5841

  Li, Bo ^a   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; AMINOOXYACETIC ACID; ANTINEOPLASTIC AGENT; AT 7519M; AZD 3965; DEOXYGLUCOSE; DICHLOROACETIC ACID; EFLORNITHINE; EPIGALLOCATECHIN GALLATE; EVEROLIMUS; FENRETINIDE; GLUTAMINE; GLYCINE; GSK 2656157; GSK 525762; LACTIC ACID; LONIDAMINE; MYC PROTEIN; PROLINE; ROSCOVITINE; SERINE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BRAIN TUMOR; CANCER CELL; CANCER INHIBITION; CELL METABOLISM; COLORECTAL CANCER; DRUG TARGETING; GLUCOSE TRANSPORT; GLYCOLYSIS; HEAD AND NECK CARCINOMA; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; METABOLIC STRESS; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHUMAN; ONCOGENE MYC; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; STOMACH CANCER; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887123920     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3629     Document Type: Article

References (62)

1. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8: 976-90.
2. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010;107: 163-224.
3. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012;151: 68-79.
4. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012;151: 56-67.
5. Malynn BA, de Alboran IM, O'Hagan RC, Bronson R, Davidson L, DePinho RA, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 2000;14: 1390-9.
6. Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol 2011;76: 369-74.
7. Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012;18: 5546-53.
8. Podar K, Anderson KC. A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle 2010;9: 1722-8.
9. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455: 679-83.
10. Kiessling A, Wiesinger R, Sperl B, Berg T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine. ChemMedChem 2007;2: 627-30.
11. Kiessling A, Sperl B, Hollis A, Eick D, Berg T. Selective inhibition of c- Myc/Max dimerization and DNA binding by small molecules. Chem Biol 2006;13: 745-51.
12. Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer 2010;1: 650-9.
13. Brooks TA, Hurley LH. The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer 2009;9: 849-61.
14. Brooks TA, Hurley LH. Targeting MYC expression through G-quadruplexes. Genes Cancer 2010;1: 641-9.
15. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013;3: 308-23.
16. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153: 320-34.
17. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904-17.
18. Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012;150: 673-84.
19. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 2010;10: 301-9.
20. Vazquez A, Markert EK, Oltvai ZN. Serine biosynthesis with onecarbon catabolism and the glycine cleavage system represents a novel pathway for ATP generation. PLoS ONE 2011;6:e25881.
21. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010;107: 2037-42.
22. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458: 762-5.
23. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 2011;476: 346-50.
24. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011;43: 869-74.
25. Meyer N, Kim SS, Penn LZ. The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol 2006;16: 275-87.
26. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324: 1029-33.
27. Wellen KE, Thompson CB. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell 2010;40: 323-32.
28. Pinheiro C, Longatto-Filho A, Azevedo-Silva J, Casal M, Schmitt FC, Baltazar F. Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr 2012;44: 127-39.
29. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3: 177-85.
30. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008;8: 51-6.
31. Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, et al. Combinatorial regulation of neuroblastoma tumor progression by NMyc and hypoxia inducible factor HIF-1alpha. Cancer Res 2010;70: 10351-61.
32. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007;27: 7381-93.
33. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007;11: 335-47.
34. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18: 54-61.
35. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 2012;15: 157-70.
36. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, et al. ATF4 regulates MYCmediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 2012;22: 631-44.
37. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucoseindependent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012;15: 110-21.
38. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007;178: 93-105.
39. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105: 18782-7.
40. Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 1990;46: 243-71.
41. Ovejera AA, Houchens DP, Catane R, Sheridan MA, Muggia FM. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl- 6-diazo-5-oxo-norleucinyl]- 6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res 1979;39: 3220-4.
42. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15: 6479-83.
43. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 2007;406: 407-14.
44. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18: 207-19.
45. Guth PS, Risey J, Briner W, Blair P, Reed HT, Bryant G, et al. Evaluation of amino-oxyacetic acid as a palliative in tinnitus. Ann Otol Rhinol Laryngol 1990;99: 74-9.
46. Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009;69: 7986-93.
47. Agrawal S, Kumar A, Srivastava V, Mishra BN. Cloning, expression, activity and folding studies of serine hydroxymethyltransferase: a target enzyme for cancer chemotherapy. J Mol Microbiol Biotechnol 2003;6: 67-75.
48. Nikiforov MA, Chandriani S, O'Connell B, Petrenko O, Kotenko I, Beavis A, et al. A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol Cell Biol 2002;22: 5793-800.
49. Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A 2012; 109: 8983-8.
50. Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest 2012;122: 4621-34.
51. Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2013;73: 1993-2002.
52. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest 2010;120: 127-41.
53. Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E, et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012;47: 349-58.
54. Ruggero D, Montanaro L,MaL, Xu W, Londei P, Cordon-Cardo C, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004;10: 484-6.
55. Wall M, Poortinga G, Stanley KL, Lindemann RK, Bots M, Chan CJ, et al. The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov 2013;3: 82-95.
56. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011;121: 1231-41.
57. Liu L, Ulbrich J, Muller J, Wustefeld T, Aeberhard L, Kress TR, et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. Nature 2012;483: 608-12.
58. Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, et al. A Sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012; 335: 348-53.
59. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010;12: 54-9.
60. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, et al. ODC1is a critical determinant ofMYCNoncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008;68: 9735-45.
61. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition ofCDK1 as a potential therapy for tumors overexpressing MYC. Nat Med 2007;13: 820-7.
62. Nilsson JA, Keller UB, Baudino TA, Yang C, Norton S, Old JA, et al. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell 2005;7: 433-44.